NCT06067698 Alpha Lipoic Acid in Ulcerative Colitis
| NCT ID | NCT06067698 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Ulcerative Colitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2025-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-10-01 with a primary completion date of 2025-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years old. * Both male and female sex. * Newly diagnosed patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline for diagnosing Ulcerative Colitis in Adults.26 * Patients treated with 5-aminosalisylic acid (mesalamine). Exclusion Criteria: * Patients with severe ulcerative colitis. * Patients with colorectal cancer. * Patients on rectal or systemic steroids. * Patients on immunosuppressants or biological therapies. * Patients with previously failed treatment with sulphasalazine. * Patients with known allergy to study medications. * History of complete or partial colectomy. * Patients with significant liver disease (fibrosis, cirrhosis, NASH, NAFLD). * Patients with other inflammatory diseases. * Patients with thyroid diseases. * Patients with arrhythmia, ischemic heart disease, and heart failure. * Patients with diabetes. * Patients on antioxidants supplement (vitamin A, C, E), selenium, co-enzyme Q. * Patients on amlodipine, levothyroxine, low strength aspirin, warfarin, atorvastatin, insulin, oral hypoglycemic, chemotherapy (drug-drug interaction).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06067698 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ulcerative Colitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06067698 currently recruiting?
Yes, NCT06067698 is actively recruiting participants. Contact the research team at ahmed.farouk.pharmacist@gmail.com for enrollment information.
Where is the NCT06067698 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06067698 clinical trial?
NCT06067698 is sponsored by Tanta University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.